Skip to main content

Advertisement

Table 3 Results of cytology and HR-HPV co-testing performed within 6 months before histological diagnosis of invasive cervical adenocarcinoma

From: Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories

CytologyHC2 testing (n = 24)Genotyping (n = 45)Total (n = 69)
Negative (%)Positive (%)Negative (%)Positive (%)Negative (%)Positive (%)
NILM3 (12.5)6 (25.0)6 (13.3)1 (2.2)9 (13.0)7 (10.1)
Unsatisfactory0 (0)1 (4.2)0 (0)1 (2.2)0 (0)2 (2.9)
ASC-US1 (4.2)4 (16.7)3 (6.7)1 (2.2)4 (5.8)5 (7.2)
ASC-H0 (0)2 (8.3)1 (2.2)5 (11.1)1 (1.4)7 (10.1)
HSIL0 (0)0 (0)0 (0)2 (4.4)0 (0)2 (2.9)
Cancer cells0 (0)2 (8.3)2 (4.4)8 (17.8)2 (2.9)10 (14.5)
AGC2 (8.3)3 (12.5)5 (11.1)10 (22.2)7 (10.1)13 (18.8)
Total6 (25.0)18 (75.0)17 (37.8)28 (62.2)23 (33.3)46 (66.7)
  1. HR-HPV, High-risk human papillomavirus; HC2, Hybrid Capture 2; NILM, negative for intraepithelial lesion or malignancy; ASC-US, Atypical squamous cells of undetermined significance; ASC-H, Atypical squamous cells—cannot exclude HSIL; HSIL, High-grade squamous intraepithelial lesion; AGC, Atypical glandular cells